Successful treatment of depot medroxyprogesterone acetate-related vaginal bleeding improves continuation rates in adolescents.
Publication/Presentation Date
3-19-2006
Abstract
High discontinuation rates for depot medroxyprogesterone acetate (DMPA) in adolescents may contribute to the number of unintended pregnancies. Many cite vaginal bleeding as a reason for discontinuing DMPA use. In this study, we attempted to determine if treating DMPA-associated vaginal bleeding with monophasic oral contraceptive pills (OCP) raised continuation rates. A total of 131 patients who reported vaginal bleeding while on DMPA were included in this study and 83 were treated with monophasic OCP. Of those who received OCP, 38.7% reported that vaginal bleeding stopped completely, 51.8% reported that vaginal bleeding stopped temporarily, and 6.0% reported no change. Overall, 94% of enrolled patients who received OCP as a treatment for DMPA-associated vaginal bleeding continued DMPA use. Our findings indicate that vaginal bleeding due to DMPA can be successfully treated, leading to improvement in continuation rates.
Volume
6
First Page
353
Last Page
355
ISSN
1537-744X
Published In/Presented At
Rager, K. M., Fowler, A., & Omar, H. A. (2006). Successful treatment of depot medroxyprogesterone acetate-related vaginal bleeding improves continuation rates in adolescents. TheScientificWorldJournal, 6, 353–355. https://doi.org/10.1100/tsw.2006.69
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
16547584
Department(s)
Department of Pediatrics
Document Type
Article